← Back to Search

Magnetic Resonance Fingerprinting for Brain Cancer

N/A

Recruiting

Led By Chaitra A Badve, MD

Research Sponsored by Case Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of intra-axial brain tumor at initial diagnosis or patients with known treated brain tumors on follow-up with concern for imaging progression

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 12 months

Awards & highlights

Study Summary

This trial is testing a new magnetic resonance fingerprinting technique to see if it can improve brain tumor diagnosis and assessment.

Who is the study for?

This trial is for adults with a new or previously treated brain tumor who can give informed consent themselves or through a legal representative. It's not for those with non-MRI safe implants, metallic foreign objects in their body, severe claustrophobia, pregnant women, prisoners, vulnerable populations, non-English speakers, or minors.Check my eligibility

What is being tested?

The study tests Magnetic Resonance Fingerprinting (MRF), an advanced MR imaging technique that quickly scans and provides detailed tissue data. This will be compared to standard imaging and clinical information to check its accuracy in diagnosing and assessing brain tumors.See study design

What are the potential side effects?

As MRF is a type of MRI scan without radiation exposure like X-rays or CT scans, it's generally considered safe. However, some may experience discomfort from the loud noises during scanning or anxiety due to being in a confined space.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a brain tumor that was either found at the start or has shown signs of growth on scans.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Prediction analysis of MRF scans

Neoplasms

T2 relaxometry value of Region of Interest (ROI) in MRF scan for each tumor type

Secondary outcome measures

In treated tumors, difference in T1 and T2 relaxation times between recurrent tumor and radiation necrosis

In treated tumors, difference in T1 relaxation times between baseline and 6 months post surgery

In treated tumors, difference in T2 relaxation times between baseline and 6 months post surgery

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Treated tumors with possible recurrenceExperimental Treatment1 Intervention

Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.

Group II: Newly Diagnosed Brain TumorsExperimental Treatment1 Intervention

Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.

0 / 1Eligibility criteria met